Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Blinklab Limited ( (AU:BB1) ) has provided an announcement.
BlinkLab Limited has received an $822,205 refund under the Australian Government’s R&D Tax Incentive program, bolstering its cash position as it advances its smartphone-based neurobehavioural assessment technology for autism. The refund, linked to a U.S. pilot study and clinical research initiatives in Australia, including collaboration with Monash University’s MAGNET study, will fund ongoing R&D activities, continued clinical studies, and broader product and regulatory development, providing greater financial flexibility as the company prepares to launch its main FDA study and commence participant enrolment.
More about Blinklab Limited
BlinkLab Limited is a digital health company founded by neuroscientists at Princeton University that has developed a smartphone-based diagnostic platform for autism and ADHD. Its lead product is an autism diagnostic aid for clinicians that uses smartphones, artificial intelligence and machine learning to support earlier and more accurate detection of autism, and the company is guided by an experienced management team and scientific advisors specialising in digital healthcare, computer vision, AI and brain development.
Average Trading Volume: 382,109
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$105.1M
Find detailed analytics on BB1 stock on TipRanks’ Stock Analysis page.